The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1

Antiviral Therapy

Volumn 12, Issue 3, 2007, Pages 401-406

  Bárcena, Rafael ^a   Moreno, Ana ^a   Del Campo, Santos ^a   Muriel, Alfonso ^a   Mateos, Maria L ^a   Garrido, Elena ^a   García, Miguel ^a   Quereda, Carmen ^a   Moreno, Santiago ^a   Moreno, Alberto ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ERYTHROPOIETIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; UNSPECIFIED SIDE EFFECT;

ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; GENETIC MARKERS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SPAIN; SPECIES SPECIFICITY; TIME FACTORS; TREATMENT FAILURE; URBAN POPULATION; VIRAL LOAD;

EID: 34249040959     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Manns MP, McHutchinson IG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, for the International Hepatitis Interventional Therapy Group. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
3. NIH Consensus Development Conference Statement: Management of Hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002; 123:2082-2099.
4. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37:600-609.
5. Davis GL, Wong JB, McHuntchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon- α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
7. Belsley DA. Conditioning Diagnostics: Collinearity and Weak Data in Regression. 1991 New York: John Wiley & Sons.
8. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetics studies. J Antimicrob Chemother 2004; 53:15-18.
9. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36:S145-S151.
10. Moreno A, Bárcena R, García-Garzón S, et al. Viral kinetics and early prediction of nonresponse to peg-IFN-α-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus. J Viral Hepat 2006; 13:466-473.
11. Carlsson T, Reichard O, Norkrans G, Bläckberg J, Sangfelt P, Wallmark E. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-a 2a and ribavirin according to virological response. J Viral Hepat 2005; 12:473-480.
12. Schiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26:780-785.
13. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persitent viremia. Gastroenterology 1999; 117:1164-1172.
14. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon-α-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32:1131-1137.
15. Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C-Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon non-responders. Control Clin Trials 2004; 25:472-92.
16. Curry M, Cárdenas A, Afdhal NH. Effect of maintenance Peg-Intron therapy on portal hypertension and its complications: results from the COPILOT study. J Hepatol 2005; 42:40. Abstract 95.
17. Poynard T, Schiff E, Terg R, et al. Sustained virologic response (SVR) in the EPIC3 trial: week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving Peg-Intron/rebetol (PR) weight based dosing (WBD). J Hepatol 2005; 42:40. Abstract 96.
18. Formann E, Jesner W, Bennet L, Ferenci P. Twice weekly administration of peginterferon-α-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat 2003; 10:271-276.
19. Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon α-2a and peginterferon α 2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antiviral Ther 2004; 9:491-197.
20. Moreno A, Bárcena R, García-Garzón S, et al. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-α-2b/ribavirin. J Hepatol 2005; 43:783-790.
21. Elinav E, Ben-Dov IZ, Ackerman E, et al. Correlation between serum alanine aminotransferase activity and age: an inverted U curve. Am J Gastroenterol 2005; 100:2201-2204.
22. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005; 40:867-872.